Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b-Reference-Cited by-同舟云学术

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

Published:1999-10 Issue:2 Volume:168 Page:131-136
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Antonelli Guido,Simeoni Eleonora,Bagnato Francesca,Pozzilli Carlo,Turriziani Ombretta,Tesoro Ramon,Di Marco Paola,Gasperini Claudio,Fieschi Cesare,Dianzani Ferdinando

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology

Reference28 articles.

1. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of a randomized controlled trial;Neurology,1995

2. Intramuscolar interferon beta-1a for disease progression in relapsing multiple sclerosis;Jacobs;Ann. Neurol.,1996

3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis;Lancet,1998

4. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis;Lancet,1998

5. In vivo development of neutralizing antibodies to interferons: an update to 1996;Antonelli;J. Inteferon Cytokine Res.,1997

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis;CNS Drugs;2022-05-19

2. Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway;Scientific Reports;2017-11-29

3. The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients;Medicine;2016-11

4. Immunogenicity considerations;Biosimilars and Interchangeable Biologics;2015-12-02

5. Evaluation of the impact of neutralizing antibodies on IFNβ response;Clinica Chimica Acta;2015-09